Cystic fibrosis epidemiology and demographics
Cystic fibrosis Microchapters
Cystic fibrosis epidemiology and demographics On the Web
American Roentgen Ray Society Images of Cystic fibrosis epidemiology and demographics
The incidence of cystic fibrosis is approximately 1 in 2500 livebirths. It is a life-limiting disease (100% mortality rate), and a cure for the disease remains elusive. Most patients with cystic fibrosis are diagnosed in first 2 years of life. The onset of symptoms is before the first month of life in 12%, between 1-6 months of age in 75%, and between 6-12 months of age in 7% of patients. Although cystic fibrosis has been reported in all racial and ethnic groups, it mostly affects Caucasians of Northern European descent. It affects men and women equally.
Epidemiology and Demographics
- The incidence of cystic fibrosis is approximately 40 in 100,000 live births worldwide.
- The incidence of cystic fibrosis is approximately 25 in 100,000 newborns in the US.
- Cystic fibrosis affects more than 30,000 people in the United States and 80,000 people worldwide.
- Cystic fibrosis is a life-limiting disease (100% mortality rate), and a cure for the disease remains elusive.
- Most patients with cystic fibrosis are diagnosed in first 2 years of life. The onset of symptoms is before the first month of life in 12%, between 1-6 months of age in 75%, and between 6-12 months of age in 7% of patients.
- Although cystic fibrosis has been reported in all racial and ethnic groups, it mostly affects Caucasians of Northern European descent.
- Cystic fibrosis is the most lethal genetic disease among Caucasians
- Cystic fibrosis is approximately reported in different ethnic groups as follow:
|Prevalence of cystic fibrosis according to race|
|Race||Prevalence (per 100,000 person years)|
- Cystic fibrosis affects men and women equally. Women with cystic fibrosis have a shortened life expectancy compared to men.
- Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR (February 2017). "Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation". J. Pediatr. 181S: S4–S15.e1. doi:10.1016/j.jpeds.2016.09.064. PMID 28129811.
- Ratjen F, Döring G (2003). "Cystic fibrosis". Lancet. 361 (9358): 681–9. doi:10.1016/S0140-6736(03)12567-6. PMID 12606185.
- Brown SD, White R, Tobin P (May 2017). "Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment". JAAPA. 30 (5): 23–27. doi:10.1097/01.JAA.0000515540.36581.92. PMID 28441669.
- Pittman JE, Ferkol TW (August 2015). "The Evolution of Cystic Fibrosis Care". Chest. 148 (2): 533–542. doi:10.1378/chest.14-1997. PMC 4524331. PMID 25764168.
- Ernst MM, Johnson MC, Stark LJ (April 2010). "Developmental and psychosocial issues in cystic fibrosis". Child Adolesc Psychiatr Clin N Am. 19 (2): 263–83, viii. doi:10.1016/j.chc.2010.01.004. PMC 2874200. PMID 20478499.
- Pettit RS, Fellner C (July 2014). "CFTR Modulators for the Treatment of Cystic Fibrosis". P T. 39 (7): 500–11. PMC 4103577. PMID 25083129.
- Cutting GR (2015). "Cystic fibrosis genetics: from molecular understanding to clinical application". Nat. Rev. Genet. 16 (1): 45–56. doi:10.1038/nrg3849. PMC 4364438. PMID 25404111.
- Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R (December 2014). "Gender differences in outcomes of patients with cystic fibrosis". J Womens Health (Larchmt). 23 (12): 1012–20. doi:10.1089/jwh.2014.4985. PMC 4442553. PMID 25495366.